Stock Update : Stock Movers on FDA Decision (ZIOP, ABT, ZLCS, ATHX)

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 4.77% to $4.17 on heavy volume after it announce that they have been granted orphan drug designation by the U.S. Food and Drug Administration for darinaparsin (Zinapar or ZIO-101).

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

ZIO-101 is a potential treatment for peripheral T-cell Lymphoma (PTCL).

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company focuses on licensing and development of small molecule drug candidates that are related to cancer therapeutics already on the market or in development and that can be developed in intravenous (IV) and/or oral forms of administration.

Abbott Laboratories (NYSE:ABT) fell 0.54% to $51.65 on heavy volume after Abbott (NYSE: ABT) and Reata Pharmaceuticals have entered into a collaborative agreement for the development and commercialization of bardoxolone methyl (bardoxolone). Bardoxolone methyl is a potential treatment of chronic kidney disease, and is currently in late Phase 2 trials.

Zalicus Inc. - Common (NASDAQ:ZLCS) fell 2.34% to $1.25 after it announces presentation of data tied to the discovery of novel synergistic drug combinations for the treatment of cancer.

According to President and CEO, Mark H.N. Corrigan, M.D.:

“These data, which were generated with our combination high-throughput screening (cHTS™) technology, support the rationale that employing a systematic approach to the discovery of novel targets and pathway interactions specific to cancer biology will lead toward development of more selective and efficacious combination therapeutics for a wide variety of cancers. Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaboration with Novartis."

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

Athersys, Inc. (NASDAQ:ATHX) rose 1.90% to $3.22 it updates on a Phase I clinical trial of MultiStem. According to the release: "New data presented by [Dr. Marc Penn, M.D., Ph.D., co-principal investigator of this study] included additional information about the nature and incidence of adverse events (AEs) over the first four months of the trial, demonstrating that the AEs were generally mild-to-moderate in nature, there was no dose dependent effect of MultiStem on AEs, and overall, MultiStem had a favorable safety profile.

About http://www.PennyStockPickReport.com

Penny Stock Pick Report offers stock update on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.